ArticleBlood advances2021
High fibrinogen γ' levels in patient plasma increase clot formation at arterial and venous shear.
Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Supramolecular engineering of fibrinogen into a fibrin matrix with enhanced bioactive properties.Bioactive materials · 2027Article
- Fibrin-bound thrombin determines clot structure and blood thrombogenicity in normofibrinogenemia and dysfibrinogenemia.Haematologica · 2026Article
- Interpretable machine learning models using peripheral blood biomarkers for diagnosis and prognosis of glottic laryngeal squamous cell carcinoma.Scientific reports · 2026Article
- Bidirectional Inflammatory Mechanisms and Hematological/Coagulation Dysregulation in Psoriasis Complicated with Atherosclerosis: A Retrospective Hospital-Based Case-Control Study Leveraging the SH-YIMED Clinical Database.Psoriasis (Auckland, N.Z.) · 2026Article
- Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis.International journal of molecular sciences · 2025Review
- Association of high γ' fibrinogen levels with adverse events in patients with COVID-19.Blood vessels, thrombosis & hemostasis · 2025Article
- Clinical Significance and Correlation of Plasma D-Dimer, Fibrinogen, and Cytokines in Idiopathic Inflammatory Myopathy.International journal of general medicine · 2025Article
- Comparative cohort study of post-acute COVID-19 infection with a nested, randomized controlled trial of ivabradine for those with postural orthostatic tachycardia syndrome (the COVIVA study).Frontiers in neurology · 2025Article
- Developing fibrin-based biomaterials/scaffolds in tissue engineering.Bioactive materials · 2024Review
- Predictive value of Caprini risk assessment model, D-dimer, and fibrinogen levels on lower extremity deep vein thrombosis in patients with spontaneous intracerebral hemorrhage.Frontiers in neurology · 2024Article
- The prognostic role of coagulation markers in the progression and metastasis of laryngeal squamous cell carcinoma.BMC cancer · 2023Article
- γ' fibrinogen levels as a biomarker of COVID-19 respiratory disease severity.Blood cells, molecules & diseases · 2023Article
- Circulating Biomarkers for Laboratory Diagnostics of Atherosclerosis-Literature Review.Diagnostics (Basel, Switzerland) · 2022Review
- Gamma' fibrinogen levels as a biomarker of COVID-19 respiratory disease severity.Research square · 2022Article
- Associations Between 25-Hydroxyvitamin D and Total and γ' Fibrinogen and Plasma Clot Properties and Gene Interactions in a Group of Healthy Black South African Women.Frontiers in cardiovascular medicine · 2022Article
- Fibrinogen and Atherosclerotic Cardiovascular Diseases-Review of the Literature and Clinical Studies.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Fibrinogen γ' accounts for 3% to 40% of plasma fibrinogen. Earlier studies indicated that fibrinogen γ' forms altered fibrin clots under static conditions, whereas clinically, altered plasma γ' levels are associated with arterial and venous thrombosis. However, the effects of static vs flow conditions on the role of γ' throughout the pathophysiological range is unknown. This study explores the effects of γ' levels on clot formation and structure in static and flow conditions. Coagulation of plasma samples with low (n = 41; 3%), normal (n = 45; 10%), or high (n = 33; 30%) γ' levels were compared with that of purified fibrinogen mixtures with increasing ratios of γ' (3%, 10%, 30%). Clots were analyzed by confocal microscopy, permeation, turbidity, and lysis techniques. In a novel 2-step flow-perfusion model, fibrinogen-deficient plasma repleted with increasing ratios of γ' (3%, 10%, 30%) or plasmas with low (n = 5, 3%) or high (n = 5, 30%) γ' were flowed over preformed platelet aggregates at arterial (500 s-1) and venous (150 s-1) shear rates. Increasing γ' percentages within the pathophysiological range (3%-30%) did not result in any change in clot-formation rates; however, it led to significantly higher clot density, thinner fibers, and slower lysis in static conditions. Under flow at arterial shear, high γ' (30%) led to faster (+44.1%-75.3%) and increased (+104%-123%) fibrin deposition, with clots exhibiting a larger volume (+253%-655%) and height (+130%-146%). These trends were magnified at venous shear. Overall, our findings demonstrate the significant impact of pathophysiological fibrinogen γ' levels on clot structure and provide new flow-dependent mechanisms to explain how γ' increases thrombosis risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.